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ABSTRACT: Somatic mutations activating telomerase reverse-trans-
criptase promoter were recently identiﬁed in several tumor types.
Here we identify frequent similar mutations in human hepatocellular
carcinomas (59%), cirrhotic preneoplastic macronodules (25%) and
hepatocellular adenomas with malignant transformation in hepato-
cellular carcinomas (44%). In hepatocellular tumors, telomerase
reverse-transcriptase- and CTNNB1-activating mutations are signiﬁ-
cantly associated. Moreover, preliminary data suggest that telome-
rase reverse transcriptase promoter mutations can increase the
expression of telomerase transcript. In conclusion, telomerase
reverse-transcriptase promoter mutation is the earliest recurrent
genetic event identiﬁed in cirrhotic preneoplastic lesions so far and
is also the most frequent genetic alteration in hepatocellular carcino-
mas, arising from both the cirrhotic or non-cirrhotic liver.
 2014 European Association for the Study of the Liver. Published
by Elsevier B.V.
Hepatocellular carcinoma (HCC) is a major public health problem
with 750,000 new cases yearly and an incidence rising worldwide
[1]. Cirrhosis affects 1% of the human population, and one-third
of them will develop HCC in their lifetime [1]. The ﬁrst genomic
hits and molecular aberrations in hepatocarcinogenesis occur at
the stages of cirrhosis and dysplastic nodules. Microenvironment
plays a critical role in cancer onset, and some signaling cascades
such as IL-6, JAK/STAT signaling, EGF, NF-jB, and lymphotoxin
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E-mail address: jmllovet@clinic.cat (J.M. Llovet).ment [2]. This ‘‘ﬁeld effect’’ has been captured in a gene signature
that identiﬁes patients at high risk of liver decompensation, HCC
development and death [3]. It is known that high grade dysplastic
nodules (HGDN) represent a clear-cut neoplastic predecessor,
since they degenerate over time in 30–65% of cases [4], and are
molecularly characterized by overexpression of TERT and activa-
tion of JAK/STAT signaling [5]. Nonetheless, so far, no relevant
gatekeeper mutations – molecular abnormalities needed but
not sufﬁcient for cancer development – have been discovered
in HCC as opposed with APC mutations in colon cancer. The cur-
rent study reported in Nature Communications [6] describes that
TERT promoter mutations are present in 25% cirrhotic macronod-
ules and up to 59% of overt HCCs (n = 305). Both discoveries are
relevant, since the former deﬁnes the ﬁrst described gatekeeper
in hepatocarcinogenesis and the later the most prevalent muta-
tion ever reported in this neoplasm.
Telomerases are proteins responsible for the maintenance of
chromosomal integrity and genome stability. Telomerase activity
is inactivated during gestation and thereafter is reactivated only
in proliferating cells and in 90% of human cancer cells, including
HCC. There are two mechanisms of reactivation of TERT activity
(a) through epigenetic regulation and (b) through somatic muta-
tions in the TERT promoter, which has been recently discovered in
melanomas, glioblastomas and other solid tumors [7]. This break-
through ﬁnding has emerged as a novel mechanism of genetic
activation in human cancers [7,8]. TERT promoter mutations
may contribute to carcinogenesis by providing a cell replicative
advantage that ultimately leads to clonal selection in cells har-
boring these mutations.TERT as gatekeeper in HCC developed on chronic liver disease
TERT mutations may cooperate with other oncogenic mutations,
such as CTNNB1, to induce cell transformation [6]. The authors
explored the origin of these mutations in the classical step-
by-step carcinogenic process, namely cirrhotic tissues, dysplastic
nodules and HCC. They found no TERT or CTNNB1 mutations in
cirrhotic tissues (Fig. 1), but identiﬁed TERT promoter mutations
in macronodules (which generally represent dysplastic nodules)
in cirrhotic tissues. In overt HCC, TERT mutations were identiﬁed14 vol. 61 j 685–687
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Fig. 1. Step-by-step hepatocarcinogenic process. In most circumstances, hepatocellular carcinoma (HCC) develops upon progression of dysplastic nodules. The study
commented [6] deﬁnes TERT as potential gatekeeper in 25% of these pre-neoplastic lesions, and in up to 59% of overt HCC cases. Exceptionally, HCC derives from hepatic
adenomas and during the carcinogenic process TERT mutation occurs later on after CTNNB1 mutations.
International Hepatologyin 59% of cases, and concomitant CTNNB1 mutations were signif-
icantly associated with these cases as opposed to tumors with no
TERTmutations (41% vs. 21%) (Fig. 1). This indicates that CTNNB1-
activating mutations might initiate liver carcinogenesis when
occurring in dysplastic cells with a background of increased TERT
levels and with TERT-promoter mutations. The authors also
reported TERT enhanced expression in almost all HCC patients,
independently of the TERT promoter mutation status. Thus,
additional investigations are needed to unravel mechanisms
increasing TERT expression alternative to TERT-promoter muta-
tion-dependent transcriptional activation.TERT as gatekeeper in HCC developed on hepatocellular
adenomas (HCA)
The authors additionally examined the presence of TERT pro-
moter mutations in HCA with and without malignant transforma-
tion. HCAs with malignant transformation showed 44% of
concurrent TERT promoter and CTNNB1 mutations, as opposed
to 0% of TERT mutation in HCA without cancer development
(Fig. 1). Accordingly, Nault et al. suggested that in these tumors
CTNNB1-activating mutations alone are not responsible for
increased TERT transcription and therefore B-catenin does not
directly regulate TERT activity, and proposed that TERT-promoter
mutations together with CTNNB1 mutations trigger HCA malig-
nant transformation.TERT as potential target for therapies
High-resolution analysis ofmolecular alterations in humanmalig-
nancies has allowed the identiﬁcation of new drivers in solid
tumors such as lung, breast ormelanoma. Recent studies have pro-
vided a broad picture of the mutational proﬁle in HCC and identi-
ﬁed an average of 30–40 mutations per tumor, among which 6–8
are considered drivers. The current study points to 60% of TERT
promoter mutation rate in HCC, conﬁrming a previous ﬁnding in
close to 50% of cases (27/61) [7]. Thus, TERT promoter mutations
emerge as the most prevalent mutations in HCC ahead of p53,686 Journal of Hepatology 201CTNNB1, ARID1A, and Axin 1. Deep-sequencing studies identiﬁed
other mutations with a prevalence below 10%, such as genes
involved in ubiquitination (KEAP1), RAS/MAPK signaling
(RPS6KA3) and oxidative stress (NFE2L2) and JAK1 in 9% of hepatitis
B virus (HBV)-related HCC, and conﬁrmed that the classical RTK
mutations (EGFR, PIK3CA orKRAS) have a lowprevalence of <5% [9].
A critical concern is whether TERT promoter mutations are
druggable targets. Diverse anticancer drugs targeting telomerases
based on immunotherapy, small molecule inhibitors and gene
therapy are currently under evaluation exhibiting modest success
in phase II and phase III clinical trials (http://clinicaltrials.gov/).
In HCC, a phase II study conducted with anti-TERT vaccine in
advanced cases did not identify objective responses or activation
of T cells [10]. Additional studies would be required to further
elucidate if TERT promoter-HCCs represent a subset of patients
amenable for anti-TERT therapies. In this sense, as recommended
by the EASL-EORTC guidelines [1], it would be recommended that
further studies testing anti-TERT therapies are conducted in
enriched populations.
In conclusion, this outstanding advancement points to a better
understanding of early events in hepatocarcinogenesis and tumor
progression, and provides a new opportunity for exploring
molecularly-tailored preventive and therapeutic approaches in
the ﬁeld.Conﬂict of interests
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